Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 10,627 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Interventions: Nerandomilast, Placebo matching nerandomilast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 25 more

Conditions: Chronic Kidney Diseases, Deficiency, Vitamin D
Interventions: Cholecalciferol; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Aurora, Colorado • Pittsburgh, Pennsylvania

Conditions: Neuroblastoma
Interventions: filgrastim, sargramostim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, conventional surgery, neoadjuvant therapy; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 2011
U.S. locations: 207
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Fibromyalgia
Interventions: [S,S]-Reboxetine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 101
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 87 more

Conditions: Refractory IPA
Interventions: PC945, Placebo; Drug
Lead sponsor: Pulmocide Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 10 more

Conditions: Primary Biliary Cirrhosis
Interventions: Seladelpar 5 mg Capsule, Seladelpar 10 mg Capsule; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 40
States / cities: Little Rock, Arkansas • Palo Alto, California • Pasadena, California + 32 more

Conditions: CNS Cancer, Meningioma, Intracranial Hemangiopericytoma, Hemangioblastoma, Neurofibromatosis
Interventions: Sunitinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 6
States / cities: Boston, Massachusetts • Basking Ridge, New Jersey • Commack, New York + 3 more

Conditions: Herpes Simplex Virus
Interventions: Novel Antiviral Drug, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 98 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more

Conditions: Vocal Fold Nodules
Interventions: Adventures in Voice: Pediatric Voice Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 4 Years to 11 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions: Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication; Device · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more

Conditions: Generalized Myasthenia Gravis
Interventions: zilucoplan (RA101495); Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 33
States / cities: Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more

Conditions: Influenza
Interventions: 4 Pillars Immunization Toolkit; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 6 Months to 18 Years
Enrollment: 87,665 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Mucopolysaccharidosis IIIB
Interventions: JR-446; Drug
Lead sponsor: JCR Pharmaceuticals Co., Ltd.; Industry
Eligibility: Up to 5 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Oakland, California • Pittsburgh, Pennsylvania • Fairfax, Virginia

Conditions: Aortic Valve Stenosis
Interventions: Echocardiography, Computed tomography, Magnetic resonance imaging, Blood biomarkers, Stress echocardiography; Other
Lead sponsor: Laval University; Other
Eligibility: 21 Years to 90 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2024
U.S. locations: 2
States / cities: Rochester, Minnesota • Pittsburgh, Pennsylvania

Conditions: Health Behavior
Interventions: Intervention group; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 11 Years and older
Enrollment: 398 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Volumetric Muscle Loss
Interventions: NO Sensor; Device
Lead sponsor: Stephen Badylak; Other
Eligibility: 22 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma
Interventions: Cetuximab, Bevacizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 98 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Alzheimer's Disease
Interventions: Florbetapir (18F), 11C-PiB; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Relapsed/Refractory Small Cell Lung Cancer
Interventions: Tarlatamab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Newark, Delaware + 13 more

Conditions: Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
Interventions: Impella 5.5 SmartAssist; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: Tampa, Florida • Indianapolis, Indiana • Minneapolis, Minnesota + 13 more

Conditions: HIV Infections, Lipodystrophy
Interventions: Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 31
States / cities: Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 20 more

Conditions: Menopause Hot Flashes
Interventions: Placebo, Fezolinetant; Drug
Lead sponsor: Rebecca Thurston; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Active Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 35
States / cities: Covina, California • Hemet, California • Los Angeles, California + 28 more

Conditions: Postoperative Pain
Interventions: Oxymorphone IR; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 8 more

Search by objective public record fields.

A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases

Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease

Combination Chemotherapy in Treating Children With Neuroblastoma

Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

Prospective Study of Voice Therapy in Children: A Pilot Study

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

From Innovation to Solutions: Childhood Influenza Vaccination Planning

A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

Multicenter Prospective Study of Low-Flow Low-Gradient Aortic Stenosis (TOPAS Study)

Raices: A Promotores Network to Improve Latino Immigrant Health

NO Sensor to Record Wound Data in Acute or Chronic Wounds

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Florbetapir Calibration to the Centiloid Scale

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

Fezolinetant and Vascular Health and Brain Health

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.